http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
심한 황달을 동반하며 악화되는 만성 B 형 간염환자에 대한 임상적 고찰
추원석(Won Suk Choo),이재명(Jae Myung Lee),조병동(Byung Dong Cho),이록윤(Rok Yun Lee),오흥국(Heung Kook Oh),정의훈(Eui Hun Jeong),김용범(Yong Bum Kim),김학양(Hak Yang Kim),박충기(Choong Kee Park),유재영(Jae Young Yoo) 대한내과학회 1996 대한내과학회지 Vol.51 No.1
N/A Objectives: Recurrent exacerbation of hepatitis activity is regarded as one of the most important etiological factor in the natural history of chronic hepatitis B in Korea. Among them the development of progressive jaundice seems to be the worst prognostic marker for the progression. This study is conducted to investigate the significance of progressive jaundice in patients with exacerbation of hepatitis H. Methods: We evaluated 30 patients with exacerbation of chronic hepatitis H. The patients were divided into two groups according to the development of jaundice. 15 patients with progressive jaundice were included in Group A, and the other 15 without jaundice were in Group B. Liver function test, serum HBV markers, HBV-DNA and immunoperoxidase staining for HBsAg and HBcAg were performed and followed-up up to one and half years. Results: 1) Among 30 patients, 27 were male and 3 were female and ages from 16 to 57(Mean in Group A;A3 8r Group B; 37) year.;. 2) Serum bilirubin was markedly elevated in Group A, 17.5-36.4(mean 28.0)mg/dL and serum pro- tein, albumin and cholesterol were also markedly decreased compare with those of Group B. 3) Serum HBV-DNA was detectable in all 26 HBeAg positive patients, but was undetectable in 4 HBeAg negative patients in Group A. 4) There was no difference of distribution of HBsAg and HBcAg in the liver tissures by immunoperoxidase staining. The staining pattern was also similar in 2 Groups, mostly cytoplasmic HBcAg. 5) In Group A, spontaneous bacterial peritonitis was complicated in all patients who developed ascites. Hut no ascites or bacterial peritonitis was found in Group B. 6) In Group A, 2 patients died during the hospitalization (within 4 weeks after developing jaundice), and one died during follow-up(15 month after initial exacerbation) 6 progressed to decompensated cirrhosis and the rest 6 were in stable state during follow up. In contrast, there was no death in group H and only 2 were progressed to decompensated cirrhosis. Conclusion: Patients with acute exacerbation of hepatitis developing jaundice showed more severe disease activity regardless of the etiological factor(s). It may be related to the immune status of the patients and/or some kinds of environmental factors which are not yet identified. It would also be necessary to identify the precore mutant infection to these type of patients and extensive treatment modalities should be investigated.
간성 뇌중 환자에서 Flumazenil 의 효과 및 안정성에 관한 전향성 연구
추원석(Won Seok Choo),최호열(Ho Yul Choi),빈중선(Joong Sun Bin),최예원(Rye Won Choi),전용철(Yong Cheol Jeon),김학양(Hak Yang Kim),박충기(Choong Kee Park),유재영(Jae Young Yoo),이병철(Byung Chul Lee) 대한내과학회 1994 대한내과학회지 Vol.46 No.4
N/A Objectivea: Ther are still many controversies on the pathogenesis of the hepatic encephalopathy. Recently, it has been postulated that endogenous benzodiazepine like substance (s) may be involved in the neuroinhibitory effect of gamma-aminobutyric acid (GABA). For this reason, benzodiazepine antagonist, flumazenil, has been advocated as a new treatment for hepatic encephalopathy. Several studies reported clinical improvement of hepatic encephalopathy in patients treated with flumazenil but these were not controlled studies. Methods: To investigate the effect of flumazenil, we performed a double-blind, prospective study in the 13 patients with hepatic encephalopathy who fulfilled the inclusion criteria of the protocol. The drug was administered intravenously (flumazenil 2.2 mg bolus injection followed by a continuous infusion with a rate of 1 mg/ h or placebo) in coded vial. After the code was open, 6 patients received flumazenil and the other 7 palcebo. The ages were 36 to 61(mean 54) years and 7 were male and 6 female. The causes of liver cirrhosis were HBV related in 7, HCV related in 3, and 3 were alcoholics. Results: In the fumazenil group, 4(67%) demonstrated immediate improvement of mental state with various degrees (from stage III to II in 1 and from stage I & II to 0 in 3). The significant and immediate improvement in the electroencephalographic (EEG) findings were noted in 3(50%), In the placebo group, however, 2(29%) showed an immediate improvement in EEG findings but only one (14%) showed the immediate improvement of mental status. There was no evidence of significant adverse reaction related to the treatment. Conclusion: This study shows that the benzodiazepine antagonist flumazenil may be effective and safe in patients with hepatic encephalopathy in the immediate mangement. Long term beneficial effect may be expected by treating the patients with more convinient oral administration.
추영국,주원석,송일찬,박세라,서상영,조진형,민성훈,김대헌,김지수,김순욱,박순주,고기성 한국식물생명공학회 2019 JOURNAL OF PLANT BIOTECHNOLOGY Vol.46 No.3
Production of therapeutic monoclonal antibodies (mAbs) using a plant platform has been considered an alternative to the mammalian cell-based production system. A plant-derived mAb CO17-1AK (mAbP COK) can specifically bind to various types of cancer cell lines. The target protein of mAbP COK is the epithelial cell adhesion molecule (EpCAM) highly expressed in human epithelial cancer cells, including breast and colorectal cancer cells. It has been hypothesized that its overexpression supports tumor growth and metastasis. A ganglioside is extended well beyond the surfaces of the various cell membranes and has roles in cell growth, inflammation, differentiation, and carcinogenesis. However, the regulation of EpCAM gene expression in breast cancers and the role of gangliosides in oncogenesis are unclear. Here, the purpose of this study was to determine the effects of mAbP COK on human breast cancer cell proliferation, apoptosis, and ganglioside expression patterns. Our results show that treatment with mAbP COK suppressed the growth of breast cancer cells and induced apoptotic cell death. It also upregulated the expression of metastasis-related gangliosides in breast cancer cells. Thus, treatment with mAbP COK may have chemo-preventive therapeutic effects against human breast cancer.